- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02773043
Evaluation of Myocardial Perfusion Reserve (EVARESERVE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Coronary artery disease is a public health problem. The measurement of myocardial perfusion reserve is a prognostic factor supplemental.
Its measure should influence the treatment and the follow up of the patients. The measurement of CRF by by one pressure-temperature sensor-tipped guide wire is a validated technique to evaluate the myocardial perfusion reserve but it is an invasive technique.
In this study, the investigators will compare this method with a non-invasive method: completely automated analysis and quantification of myocardial blood flow from DICOM files corresponding to stress and rest images was developed with a new camera CZT SPECT.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
La Tronche, France, 38700
- CHU Michallon
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Myocardial scintigraphy with pharmacologic stress and abnormal results
- Coronarography indicated
- Informed consent
Exclusion Criteria:
- Pregnant woman
- Patient with terminal illness
- Terminal renal failure
- Allergy to iodine
- Informed consent impossible
- Patient under legal protection
- History of coronary artery bypass surgery
- Contraindications for adenosine: asthmatic patients, second or third-degree AV block without pacemaker or sick sinus syndrome. Systolic blood pressure less than 90 mmHg. Recent use of dipyramidole or dipyramidole-containing medications. Methyl xanthenes such as aminophylline caffeine or theobromine block the effect of adenosine and should be held for at least 12 hours prior to the test. Known hypersensitivity to adenosine. Unstable acute myocardial infarction or acute coronary syndrome.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: non invasive imaging technique
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation between the measure of the coronary flow reserve with an invasive reference method (thermodilution) and a new non-invasive method in scintigraphy to measure the myocardial perfusion reserve
Time Frame: an average of 1 year
|
Coronary flow reserve by thermodilution is the ratio between mean transit time of a room temperature 3-ml bolus of saline during rest and maximal hyperemia. Coronary flow reserve by CZT camera is given by ratio between Mycoardial perfusion during rest and maximal hyperemia. Myocardial perfusion is given by new software. |
an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of the myocardial perfusion reserve measuring the CRF by thermodilution.
Time Frame: an average of 1 year
|
Coronary flow reserve by thermodilution is the ratio between mean transit time of a room temperature 3-ml bolus of saline during rest and maximal hyperemia.
|
an average of 1 year
|
|
Evaluation of the myocardial perfusion reserve in scintigraphy by the same operator over different time scales and by two different operators.
Time Frame: an average of 1 year
|
Coronary flow reserve by CZT camera is given by ratio between Mycoardial perfusion during rest and maximal hyperemia.
Myocardial perfusion is given by new software.
|
an average of 1 year
|
|
Study the correlations between the level of soluble VE-cadherin (sVE) and the other indicators of coronary endothelial involvement (CRF and RMP).
Time Frame: Day of coronarography
|
Blood test for soluble VE-cadherin (sVE), CRF, RMP
|
Day of coronarography
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gilles Barone-Rochette, MD, PhD, University Hospital, Grenoble
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 38RC14.214
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.